Under a simulation model, even a narrow expansion of coverage for GLP-1s comes at a cost because the prices are so high
A randomized trial comparing dose reduction, temporary discontinuation, and symptomatic treatment would be valuable but has not been conducted
Specifically, GLP-1RAs exert protective effects on exercise-induced cardiomyopathy via increasing autophagy, reducing inflammation-related proteins and ROS generation via restoring the expression of catalase and manganese superoxide dismutase (MnSOD) [81]
Instead, they extended the GLP-1 Bridge through the end of 2027 to ensure immediate, uninterrupted access to these medications
What are the biggest safety concerns with GLP1 use
This approach is still emerging but represents an interesting frontier for thyroid patients who want immune-modulating effects without aggressive weight loss